A Survival God for the Age of Abundance,” Peter H. Diamandis and Steven Kotler explore what it means to be human in a world ...

From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...

If you’re confused about the growing landscape of weight loss drugs, here is a concise breakdown of their mechanisms, ...

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies ...

Cell death research has emerged as a cornerstone for understanding the pathogenesis of neurological disorders. Neurons and glial cells in the central ...

The data to be presented show that Geminii's bioelectronic therapy slowed tumor growth, extended survival, and enhanced the activity of chemoradiation in multiple preclinical NSCLC models without ...

An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including ...

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of ...

Pancreatic cancer is often detected in late stages due to its location in the body. Tumors grow undetected within the gut and ...

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications; First-in-class METTL3 inhibitor reprograms malignant progenitor cells by modu ...

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation ...